Finabase

    • Login
    • Categories
    Home Watchlists Portfolios Map Forex Futures Crypto Comparisons Alerts Screeners Backtests vTrading Settings Forum
    1. Home
    2. ISEE
    • Alert
    • Note
    ISEE
    IVERIC bio, Inc.
    24.17
    +
    0.46
    1.94%
    9 x 22.27
    13 x 24.62
    bid
    ask
    11 @ 04:00 PM
    24.01-0.16 (0.66%)
    Bearish 2
    Bullish 24
    sentiment
    23.57
    day range
    24.52
    9.12
    52 week range
    24.56
    04:00 PM
    V: 1.56M
    C: 24.17
    L: 23.57
    H: 24.52
    O: 23.90
    loading chart ...
    • 1d
    • 5d
    • 1m
    • 3m
    • 6m
    • ytd
    • 1y
    • 2y
    • 5y
    • max
    • PDF
    • Full Chart
    • Stats
    • Watchlist
    • Portfolio
    Prev Close23.71
    Open23.90
    Low23.57
    High24.52
    Volume1.56M
    Avg. Volume2.42M
    Market Cap3.31B
    Inst. Own109.58%
    Beta1.10
    Short Ratio3.31
    Div & Yield0.00 /
    EPS-1.51
    P/E
    1yr Target31.17
    50day MA21.91
    200day MA17.83
    ^DJI
    Dow Jones Industrial Average
    32237.50
    05:02 PM
    +
    132.30
    0.41%
    ^IXIC
    NASDAQ Composite
    11824.00
    05:15 PM
    +
    36.60
    0.31%
    ^GSPC
    S&P 500
    3970.99
    05:02 PM
    +
    22.27
    0.56%
    AAPL
    160.23
    -0.02 (0.01%)
    Apple Inc.
    160.25
    8 @ 04:00 PM
    8 x 160.20
    8 x 160.03
    +
    1.32
    0.83%
    GOOG
    106.50
    +0.44 (0.41%)
    Alphabet Inc.
    106.06
    10 @ 04:00 PM
    10 x 106.30
    9 x 106.29
    -
    0.20
    0.19%
    AMZN
    98.44
    +0.31 (0.32%)
    Amazon.com, Inc.
    98.13
    12 @ 04:00 PM
    10 x 98.42
    13 x 98.35
    -
    0.58
    0.59%
    MSFT
    280.94
    +0.37 (0.13%)
    Microsoft Corporation
    280.57
    9 @ 04:00 PM
    8 x 280.94
    9 x 280.96
    +
    2.91
    1.05%
    BABA
    87.17
    +0.27 (0.31%)
    Alibaba Group Holding Limited
    86.90
    12 @ 04:02 PM
    14 x 87.03
    10 x 87.50
    +
    0.38
    0.44%
    NFLX
    329.70
    +1.31 (0.40%)
    Netflix, Inc.
    328.39
    19 @ 04:00 PM
    30 x 329.00
    8 x 328.69
    +
    8.02
    2.50%
    TSLA
    190.21
    -0.20 (0.11%)
    Tesla, Inc.
    190.41
    12 @ 04:00 PM
    12 x 190.21
    12 x 190.19
    -
    1.81
    0.94%
    NVDA
    267.70
    -0.09 (0.03%)
    NVIDIA Corporation
    267.79
    11 @ 04:00 PM
    14 x 267.70
    8 x 267.71
    -
    4.12
    1.52%
    AMD
    98.18
    +0.23 (0.23%)
    Advanced Micro Devices, Inc.
    97.95
    8 @ 04:00 PM
    8 x 98.06
    8 x 98.20
    -
    2.33
    2.32%
    MU
    61.33
    +0.17 (0.28%)
    Micron Technology, Inc.
    61.16
    25 @ 04:00 PM
    31 x 61.20
    18 x 61.48
    -
    0.18
    0.29%
    SPY
    396.46
    +0.71 (0.18%)
    SPDR S&P 500 ETF Trust
    395.75
    12 @ 04:00 PM
    14 x 396.42
    9 x 396.50
    +
    2.58
    0.66%
    TQQQ
    25.93
    +0.11 (0.43%)
    ProShares UltraPro QQQ
    25.82
    339 @ 04:00 PM
    270 x 25.89
    407 x 25.90
    +
    0.26
    1.02%
    BRK-A
    442765.00
    -10301.00 (2.27%)
    Berkshire Hathaway Inc.
    453066.00
    10 @ 04:02 PM
    12 x 450000.00
    8 x 456887.00
    +
    316.00
    0.07%
    Day Gain
    Gain
    Market Val
    Costs
    Cash
    Portfolio
    Realized
    Dividend
    • Summary
    • Discussion
    • News
    • Signals
    • Financials
    • Alerts
    • Notes
    • Chart
    • Backtest
    News ...
    Here’s Why You Should Add IVERIC bio (ISEE) to Your Watchlist news.google.com •
    These Are the Top 10 Holdings of David Kim 247wallst.com •
    Why Is Iveric Bio (ISEE) Stock Up 25% Today? investorplace.com •
    IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript seekingalpha.com •
    Iveric Bio to Present at Upcoming Investor Conferences businesswire.com •
    Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio investors.com •
    Profile ...
    IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
    Earning ...
    Date For Estimate Reported Surprise surprise %
    2023-05-03 2023-03 -0.45 N/A N/A N/A
    2023-03-01 2022-12 -0.37 -0.47 -0.1 -27.03%
    2022-11-03 2022-09 -0.4 -0.35 0.05 12.50%
    2022-07-26 2022-06 -0.31 -0.41 -0.1 -32.26%
    2022-05-04 2022-03 -0.29 -0.29 N/A N/A
    2022-02-24 2021-12 -0.24 -0.29 -0.05 -20.83%
    Upgrade / Downgrade ...
    Date Firm Action From To
    2023-03-02 HC Wainwright & Co. Upgrade Buy
    2023-02-21 B. Riley Securities Upgrade Neutral
    2023-02-17 HC Wainwright & Co. Upgrade Buy
    2022-11-10 Jefferies Downgrade Buy Hold
    2022-11-04 HC Wainwright & Co. Upgrade Buy
    2022-09-08 Stifel Upgrade Buy
    Insider Holder ...
    Date Name Relation Quantity Description
    2022-07-14 BLUMENKRANZ MARK S Director 17.50K Conversion of Exercise of derivative security
    2023-01-02 CARROLL DAVID FRANCIS Chief Financial Officer 68.47K Sale
    2023-01-01 DUGEL PRAVIN U President 148.72K Conversion of Exercise of derivative security
    2022-12-12 GIBNEY ANTHONY S. Officer 42.79K Conversion of Exercise of derivative security
    2022-05-10 GRAVES ADRIENNE L Director 7.50K Conversion of Exercise of derivative security
    2023-01-04 MILLER CHRISTINE ANN Director 5.00K Conversion of Exercise of derivative security
    Institution Ownership ...
    Report Date Organization Position Value Percentage
    2022-12-30 Vanguard Group, Inc. (The) 10.15M 245.37M 7.40%
    2022-12-30 Blackrock Inc. 9.75M 235.69M 7.11%
    2022-12-30 Deep Track Capital, LP 7.88M 190.41M 5.75%
    2022-12-30 Avoro Capital Advisors LLC 6.75M 163.15M 4.92%
    2022-12-30 State Street Corporation 6.34M 153.16M 4.62%
    2022-12-30 Tcg Crossover Management, Llc 5.14M 124.26M 3.75%
    Fund Ownership ...
    Report Date Organization Position Value Percentage
    2022-12-30 SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 3.81M 92.16M 3.16%
    2022-09-29 Vanguard Total Stock Market Index Fund 3.48M 84.09M 2.88%
    2022-12-30 iShares Russell 2000 ETF 3.06M 73.92M 2.53%
    2022-12-30 Smallcap World Fund 2.16M 52.31M 1.79%
    2022-09-29 Price (T.Rowe) Health Sciences Fund 1.61M 38.81M 1.33%
    2022-09-29 Vanguard Extended Market Index Fund 1.50M 36.23M 1.24%
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • C
      csrqf84t9y last edited by

      Take profits and head too $OCGN for there eye and Vaxx run next…

      1 Reply Last reply Reply Quote 0
      • E
        evelliquette last edited by

        $ISEE me shorting this one……it’s going down

        1 Reply Last reply Reply Quote 0
        • H
          hu7rb5jzei last edited by

          Only the big dogs know. Us retail slobs have to guess on the up one no news.

          1 Reply Last reply Reply Quote 0
          • H
            hu7rb5jzei last edited by

            Good luck on the cash secured puts. I hope you don’t get burned. Almost too good to be true.

            1 Reply Last reply Reply Quote 0
            • H
              hu7rb5jzei last edited by

              Something is Brewing.

              1 Reply Last reply Reply Quote 0
              • H
                hu7rb5jzei last edited by

                Will it touch 11 or 9 first?

                1 Reply Last reply Reply Quote 0
                • H
                  hu7rb5jzei last edited by

                  Why is this selling off so hard?

                  1 Reply Last reply Reply Quote 0
                  • D
                    dcschaap last edited by

                    $ISEE you at $10!

                    1 Reply Last reply Reply Quote 0
                    • M
                      maynall44 last edited by

                      $OBSV: Surprise earning by 113% above est $16-$37
                      .
                      $CAPR : Covid-19 Play...News coming this month 14th

                      $MARK : Still time to get in under $4 very under value.

                      1 Reply Last reply Reply Quote 0
                      • 1 / 1
                      • First post
                        Last post
                      • Here’s Why You Should Add IVERIC bio (ISEE) to Your Watchlist
                        news.google.com •

                      • These Are the Top 10 Holdings of David Kim
                        247wallst.com •

                      • Why Is Iveric Bio (ISEE) Stock Up 25% Today?
                        investorplace.com •

                      • IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
                        seekingalpha.com •

                      • Iveric Bio to Present at Upcoming Investor Conferences
                        businesswire.com •

                      • Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
                        investors.com •

                      • These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022
                        247wallst.com •

                      • Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
                        businesswire.com •

                      • IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
                        zacks.com •

                      • Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura
                        seekingalpha.com •

                      • Why Is Iveric Bio (ISEE) Stock Up 56% Today?
                        investorplace.com •

                      • 7 Cheap Biotech Stocks to Buy Now
                        investorplace.com •

                      • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2022 Results - Earnings Call Transcript
                        seekingalpha.com •

                      • Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
                        businesswire.com •

                      • Trial Results Set to Make or Break Small-Cap Pharma Stocks
                        gurufocus.com •

                      • IVERIC bio: A First Take
                        seekingalpha.com •

                      • Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
                        seekingalpha.com •

                      • Iveric Bio to Present at the UBS Global Healthcare Conference 2022
                        businesswire.com •

                      • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2022 Results - Earnings Call Transcript
                        seekingalpha.com •

                      • Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks
                        benzinga.com •

                      • Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market
                        seekingalpha.com •

                      • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2021 Results - Earnings Call Transcript
                        seekingalpha.com •

                      • IVERIC bio (ISEE) is on the Move, Here's Why the Trend Could be Sustainable
                        zacks.com •

                      • 7 A-Rated Biotechs to Buy for the Long Run
                        investorplace.com •

                      • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2021 Results - Earnings Call Transcript
                        seekingalpha.com •

                      • Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
                        seekingalpha.com •

                      • ISEE Stock: Why It Significantly Increased Yesterday
                        pulse2.com •

                      • Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
                        businesswire.com •

                      • Here's Why Iveric Bio Stock Is Rocketing Higher Today
                        fool.com •

                      • ISEE Stock: Why Rival Eye Drug Developer's Disappointment Is a Boon to IVERIC bio
                        investorplace.com •

                      • Why IVERIC Bio Shares Are Soaring Today
                        benzinga.com •

                      • Why Are Iveric Bio Shares Surging In Premarket Friday?
                        benzinga.com •

                      • New Strong Sell Stocks for August 18th
                        zacks.com •

                      • Implied Volatility Surging for IVERIC bio (ISEE) Stock Options
                        zacks.com •

                      • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2021 Results - Earnings Call Transcript
                        seekingalpha.com •

                      • Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
                        businesswire.com •

                      • Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule
                        businesswire.com •

                      • Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
                        pennystocks.com •

                      • Iveric Bio Appoints Christopher Simms as Chief Commercial Officer
                        businesswire.com •

                      • IVERIC bio (ISEE) Enters Overbought Territory
                        zacks.com •

                      • Iveric Bio Raises $100M Via Equity To Fund Zimura Development In Geographic Atrophy
                        benzinga.com •

                      • IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
                        businesswire.com •

                      • IVERIC bio, Inc. Announces Proposed Offering of Common Stock
                        businesswire.com •

                      • Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?
                        zacks.com •

                      • IVERIC bio Stock Increased 11.87%: Why It Happened
                        pulse2.com •

                      • ISEE Stock Price Increases Over 30% Pre-Market: Why It Happened
                        pulse2.com •

                      • Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
                        businesswire.com •

                      • Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration
                        benzinga.com •

                      • Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors
                        businesswire.com •

                      • Iveric Bio to Host Investor Symposium on Dry Age-Related Macular Degeneration on June 18, 2021
                        businesswire.com •

                      • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2021 Results - Earnings Call Transcript
                        seekingalpha.com •

                      • New Strong Sell Stocks for April 26th
                        zacks.com •

                      • New Strong Sell Stocks for April 21st
                        zacks.com •

                      • New Strong Sell Stocks for April 6th
                        zacks.com •

                      • David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund
                        businesswire.com •

                      • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
                        businesswire.com •

                      • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2020 Results - Earnings Call Transcript
                        seekingalpha.com •

                      • Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results
                        businesswire.com •

                      • Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
                        businesswire.com •

                      • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript
                        seekingalpha.com •

                      • 4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)
                        insidermonkey.com •

                      • Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com
                        businesswire.com •

                      • Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, & Market Shares - ResearchAndMarkets.com
                        businesswire.com •

                      • IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results
                        finance.yahoo.com •

                      • IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
                        finance.yahoo.com •

                      • World Retinal Biologics Market: Growth, Trends and Forecasts (2020-2025) - ResearchAndMarkets.com
                        businesswire.com •

                      • IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
                        finance.yahoo.com •

                      • Worsening eye sight doesn't stop for Covid, neither did we
                        irishtimes.com •

                      • IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020
                        finance.yahoo.com •

                      • What You Need To Know About IVERIC bio, Inc.'s (NASDAQ:ISEE) Investor Composition
                        finance.yahoo.com •

                      • Did Hedge Funds Make The Right Call On IVERIC bio, Inc. (ISEE) ?
                        finance.yahoo.com •

                      • IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors
                        finance.yahoo.com •

                      • Two Sigma Advisers LP Has $258,000 Stock Position in IVERIC bio Inc (NASDAQ:ISEE)
                        thelincolnianonline.com •

                      • 17,273 Shares in IVERIC bio Inc (NASDAQ:ISEE) Purchased by JPMorgan Chase & Co.
                        thelincolnianonline.com •

                      • Moving Average Crossover Alert: IVERIC bio
                        finance.yahoo.com •

                      • Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
                        seekingalpha.com •

                      • Juvenile Macular Degeneration (JMD) Industry Report 2020: Overview of Therapeutic Pipeline Activity and Assessment of Products - ResearchAndMarkets.com
                        businesswire.com •

                      • IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
                        finance.yahoo.com •

                      • Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News
                        seekingalpha.com •

                      • Two Sigma Investments LP Invests $675,000 in IVERIC bio Inc (NASDAQ:ISEE)
                        thelincolnianonline.com •

                      • Regeneron Pharmaceuticals : to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014 | MarketScreener
                        marketscreener.com •

                      • 822,050 Shares in IVERIC bio Inc (NASDAQ:ISEE) Acquired by Deutsche Bank AG
                        thelincolnianonline.com •

                      • IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds
                        finance.yahoo.com •

                      • NOVARTIS AG : Buy rating from Oddo | MarketScreener
                        marketscreener.com •

                      • Bayer : contributes an additional 50 million units of treatment to the World Federation of Hemophilia Humanitarian Aid Program | MarketScreener
                        marketscreener.com •

                      • Novartis : discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts | MarketScreener
                        marketscreener.com •

                      • IVERIC bio Inc (NASDAQ:ISEE) Receives Consensus Rating of “Hold” from Analysts
                        thelincolnianonline.com •

                      • IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
                        finance.yahoo.com •

                      • IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement
                        finance.yahoo.com •

                      • Specsavers stores have reopened for eye tests across Cambridgeshire
                        cambridge-news.co.uk •

                      • Specsavers: England stores open for routine eye tests from today - what to expect
                        express.co.uk •

                      • Cowen & Co. Maintains a Buy Rating on IVERIC bio (ISEE) - Markets
                        markets.co •

                      • Novartis : Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis | MarketScreener
                        marketscreener.com •

                      • Is IVERIC bio, Inc. (ISEE) Going to Burn These Hedge Funds?
                        finance.yahoo.com •

                      • Novartis : manufactures and donates 27,000 units of hand sanitizer to New York State | MarketScreener
                        marketscreener.com •

                      • IVERIC bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings: Continuous Positive Treatment Effect with Favorable Safety Profile in Geographic Atrophy Secondary to Age-Related Macular Degeneration in a Phase 3 Trial
                        finance.yahoo.com •

                      • IVERIC bio to Announce Zimura® 18 Month Data from the OPH2003 Phase 3 Clinical Trial in Geographic Atrophy Secondary to Age-Related Macular Degeneration and Host Conference Call on Monday, June 15, 2020
                        finance.yahoo.com •

                      • Fortress Biotech Announces Publication of Study on Estimated Birth Prevalence of Menkes Disease in Molecular Genetics and Metabolism Reports
                        einpresswire.com •

                      • Global Leukemia Therapeutics Market Forecast and Opportunities to 2025 - ResearchAndMarkets.com
                        businesswire.com •

                      • Correction to Treatments for Macular Degeneration Article on June 8 -- Journal Report | MarketScreener
                        marketscreener.com •

                      Copyright © 2022 finabase.io